Novartis Spent $12 Billion on an RNA Drug. It Just Flopped.

RNA drugs work beautifully in the liver, where biology cooperates. The liver basically vacuum-cleans the bloodstream, sucking up particles that happen to include RNA therapeutics. Muscle is a completely different story. The drug gets chewed up in the bloodstream, filtered out by the kidneys, hoarded by the liver, and even when some of it reaches muscle cells, it often gets trapped inside cellular compartments (called endosomes) where it's degraded before doing its job.

The pattern across the field is consistent: it's not that the biology of RNA silencing doesn't work. It's that too little drug actually reaches the muscle, and what does arrive is spread unevenly. Developers have tried cranking up doses to compensate, but that creates toxicity problems. It's a Goldilocks challenge where nobody has found "just right" yet.

Collateral Damage Across the Sector

When Novartis's results dropped, the blast radius extended well beyond one stock ticker. Dyne Therapeutics, which is developing its own DM1 treatments, saw its shares plunge roughly 31% in premarket trading, falling to around $16.76 on September 8. By the close, the stock was down about 6.4%.

This wasn't about anything specific to Dyne's programs. It was a class-risk repricing: investors collectively reassessing whether any RNA-based approach can work in muscle disease. When the biggest pharma company in the room spends $12 billion and still can't crack it, the market starts asking uncomfortable questions about everyone else.

What Novartis Does Next

Novartis says it's "evaluating the full dataset" and will "engage with health authorities" to figure out the next steps. That's corporate for "we're not sure yet." The safety data was reportedly consistent with earlier studies, so the drug doesn't appear dangerous; it just doesn't appear to work well enough on the measure that matters most.

The company pointed to signals in secondary and exploratory analyses, but they haven't released the actual numbers. Until they do, it's hard to know whether those signals represent a genuine glimmer of hope or the kind of post hoc data mining that makes statisticians cringe.

The Bigger Picture for Novartis's RNA Ambitions

One failed trial doesn't sink a strategy, but it certainly puts pressure on everything else in the pipeline. Novartis has been deliberately rebuilding its portfolio around RNA-enabled platforms, betting that these technologies will drive growth and launch new products before 2030.

That bet now looks riskier. The Avidity acquisition gave Novartis three late-stage programs and a novel delivery platform. If the platform's first major Phase III readout is a miss, investors will naturally wonder about the others. And analysts who described the RNA strategy as a "large and risky bet on emerging biology" are probably feeling vindicated this morning.

For the many patients in the U.S. and Europe living with DM1, the failure stings in a different way. This is a disease with zero approved disease-modifying treatments. Patients rely on supportive care: managing symptoms without addressing the underlying cause. Del-desiran was one of the furthest-along experimental therapies, and its stumble leaves a painful gap.

The Takeaway

Novartis's del-desiran failure is a three-layer story. Layer one: a $12 billion acquisition just lost a big chunk of its thesis. Layer two: the broader neuromuscular RNA field just got a reality check on its hardest unsolved problem (getting drugs into muscle). Layer three: patients with a devastating disease are still waiting.

RNA therapeutics remain one of the most exciting areas in medicine. But excitement and execution are two very different things, and right now, the gap between them is roughly $12 billion wide.

Roche Just Paid $1.53 Billion for a Drug That's Never Been in a Human

Roche just locked up exclusive global rights to a preclinical trispecific antibody from Chinese biotech Simcere Zaiming for up to $1.53 billion. The drug has never been tested in a human, but it targets B cells in a way Roche's legacy blockbusters can't.